Clinical Trials

Below is a list of currently active Phase II, III and IV trials. You can also search for a specific clinical trial using the field provided above.

  • Combo Chemo With or Without Torisel Treating Rhabdomyosarcoma

    To compare the EFS and the OS of patients with IR RMS treated with surgery , radiotherapy , and Vac alternating with VI(VAC/VI) to that of patients treated with surgery , radiotherapy and VAC/VI plus temsirolimus (TORI) To compare the outcome of patietns based on their FOXO1 fusioin gene partener by evaluating PAX3 vs PAX7 in all patients found to be FOXO1 fusion positive . To compare the outcome of patients based on their FDG-PET response at Week 9 ( positive or negative ) , as assessed by Deauville Criteria

  • Blinatumomab in Treating Younger Patients W/Relapsed B-cell ALL

  • Therapy for Down syndrome kids with AML

    To determine the 2-year event-free-survival (EFS) for children with standard risk DS AML (MRD-negative after one cycle of induction therapy) after elimination of HD Ara-C from the treatment regimen. To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS.

  • Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Loc

    Determine the Clinical Benefit Rate (CBR) at 24 weeks amongst patients receiving triple therapy with ribociclib + everolimus + exemestane, for advanced/metastatic HR+, HER2-negative breast cancer following progression on CDK 4/6 inhibitor.

  • Long-term Safety and Efficacy Study of Adalimumab in Pediatric Su

    This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.

  • Dinutuximab in Combo w/ Sargramostim for Recurrent Osteosarcoma

    This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a specific target on the surface of cancer cells. It then attaches to the cancer cells and kills them, without harming normal cells. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer cells.

  • GM-CSF in Incompletely Resected or Recurrent Ependymoma

    This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.

  • Study of ONO-4538 in Esophageal Cancer

    Endpoint Classification: Efficacy Study

  • Study of the safety and PK of Cobimetinib Pts with Solid Tumors

    This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable and for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.

  • A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma

    This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a specific target on the surface of cancer cells. It then attaches to the cancer cells and kills them, without harming normal cells. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer cells.